Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory to Chemotherapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Large-scale testing (Phase 3)Study completedNCT03250338
What this trial is testing

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc. 106
Large-scale testing (Phase 3)Study completedNCT01955837
What this trial is testing

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Who this might be right for
Colorectal Cancer
Taiho Pharmaceutical Co., Ltd. 406
Not applicableUnknownNCT00264056
What this trial is testing

Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases

Who this might be right for
Advanced Metastastic Malignant MelanomaRefractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases
Fachklinik Hornheide an der Universität Münster 26
Testing effectiveness (Phase 2)UnknownNCT02060656
What this trial is testing

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust 92
Testing effectiveness (Phase 2)Study completedNCT05289856
What this trial is testing

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Who this might be right for
Cancer
Johannes Gutenberg University Mainz 30
Testing effectiveness (Phase 2)Ended earlyNCT00792831
What this trial is testing

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Italfarmaco 3
Testing effectiveness (Phase 2)Ended earlyNCT03457142
What this trial is testing

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Roswell Park Cancer Institute 15
Testing effectiveness (Phase 2)WithdrawnNCT04882163
What this trial is testing

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Celgene
Early research (Phase 1)Study completedNCT01445522
What this trial is testing

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Who this might be right for
NeoplasmsLymphoma
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT04827719
What this trial is testing

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 38
Testing effectiveness (Phase 2)Study completedNCT01121406
What this trial is testing

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Boehringer Ingelheim 110
Testing effectiveness (Phase 2)Ended earlyNCT01904253
What this trial is testing

Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Who this might be right for
Small Cell Lung Cancer (SCLC)
Taiho Oncology, Inc. 18
Not applicableEnded earlyNCT03634319
What this trial is testing

Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union

Who this might be right for
Glaucoma, Open-Angle
MicroOptx 10
Large-scale testing (Phase 3)Looking for participantsNCT06387069
What this trial is testing

Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hutchmed 316
Testing effectiveness (Phase 2)WithdrawnNCT02167360
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic Leukemia
Abramson Cancer Center at Penn Medicine
Large-scale testing (Phase 3)Active Not RecruitingNCT04579224
What this trial is testing

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+2 more
National Cancer Institute (NCI) 184
Testing effectiveness (Phase 2)Ended earlyNCT00879619
What this trial is testing

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Who this might be right for
Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer+3 more
John P. Fruehauf 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Study completedNCT00331344
What this trial is testing

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 100
Next Page